Polo-like kinase 1 inhibitors in human cancer therapy: development and therapeutic potential
Polo-like kinase 1 (PLK1) plays an important role in a variety of cellular functions, including
the regulation of mitosis, DNA replication, autophagy, and the epithelial–mesenchymal …
the regulation of mitosis, DNA replication, autophagy, and the epithelial–mesenchymal …
The role of Plk3 in oncogenesis
C Helmke, S Becker, K Strebhardt - Oncogene, 2016 - nature.com
The polo-like kinases (Plks) encompass a family of five serine/threonine protein kinases that
play essential roles in many cellular processes involved in the control of the cell cycle …
play essential roles in many cellular processes involved in the control of the cell cycle …
Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer
ABSTRACT Introduction Polo Like Kinase 1 (PLK1) is a key regulator of mitosis and its
overexpression is frequently observed in a wide variety of human cancers, while often being …
overexpression is frequently observed in a wide variety of human cancers, while often being …
Small molecules that target phosphorylation dependent protein–protein interaction
N Watanabe, H Osada - Bioorganic & medicinal chemistry, 2016 - Elsevier
Protein–protein interaction is one of the key events in the signal transduction pathway. The
interaction changes the conformations, activities, localization and stabilities of the proteins …
interaction changes the conformations, activities, localization and stabilities of the proteins …
Novel macrocyclic peptidomimetics targeting the polo-box domain of polo-like kinase 1
The polo-box domain (PBD) of Plk1 is a promising target for cancer therapeutics. We
designed and synthesized novel phosphorylated macrocyclic peptidomimetics targeting …
designed and synthesized novel phosphorylated macrocyclic peptidomimetics targeting …
Molecularly Imprinted Polymers for Highly Specific Bioorthogonal Catalysis inside Cells
Z Gao, Q Shao, J Xing, Y Liang, F Meng… - Angewandte …, 2024 - Wiley Online Library
Transition metal catalysts (TMCs) mediated bioorthogonal catalysis expand the chemical
possibilities within cells. Developing synthetic TMCs tools that emulate the efficiency and …
possibilities within cells. Developing synthetic TMCs tools that emulate the efficiency and …
Peptidomimetic Polo‐Box‐Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor
M Baxter, D Chapagai, S Craig, C Hurtado… - …, 2020 - Wiley Online Library
The polo‐box domain (PBD) of PLK1 determines mitotic substrate recognition and
subcellular localization. Compounds that target PLK1 selectively are required due to the …
subcellular localization. Compounds that target PLK1 selectively are required due to the …
Polo-like kinase 1 inhibition in NSCLC: Mechanism of action and emerging predictive biomarkers
JA Stratmann, M Sebastian - Lung Cancer: Targets and Therapy, 2019 - Taylor & Francis
Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Due to
often unspecific disease symptoms, locally advanced or metastatic disease is diagnosed in …
often unspecific disease symptoms, locally advanced or metastatic disease is diagnosed in …
Development of bifunctional inhibitors of polo‐like kinase 1 with low‐nanomolar activities against the polo‐box domain
A Scharow, D Knappe, W Reindl, R Hoffmann… - …, 2016 - Wiley Online Library
Abstract Polo‐like kinase 1 (Plk1), a validated cancer target, harbors a protein–protein
interaction domain referred to as the polo‐box domain (PBD), in addition to its enzymatic …
interaction domain referred to as the polo‐box domain (PBD), in addition to its enzymatic …
Inhibitors of the Polo‐Box Domain of Polo‐Like Kinase 1
A Berg, T Berg - ChemBioChem, 2016 - Wiley Online Library
Abstract Polo‐like kinase 1 (Plk1), a key player in mitosis, is overexpressed in a wide range
of tumor types and has been validated as a target for tumor therapy. In addition to its N …
of tumor types and has been validated as a target for tumor therapy. In addition to its N …